myos corp (MYOS:OTC US)
myos corp (MYOS) Snapshot
|
Open
$0.12
|
Previous Close
$0.12
|
|
|
Day High
$0.12
|
Day Low
$0.12
|
|
|
52 Week High
06/20/12 - $0.50
|
52 Week Low
04/8/13 - $0.08
|
|
|
Market Cap
13.4M
|
Average Volume 10 Days
274.1K
|
|
|
EPS TTM
--
|
Shares Outstanding
111.4M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
myos corp (MYOS) Related Businessweek News
No Related Businessweek News Foundmyos corp (MYOS) Details
MYOS Corporation, a development stage company, focuses on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining or improving the health and performance of muscle tissue. It develops MYO-T12, a natural-myostatin inhibitor that is used to optimize biological activity. The company was formerly known as Atlas Therapeutics Corporation and changed its name to MYOS Corporation in May 2012. MYOS Corporation was founded in 2007 and is based in Cedar Knolls, New Jersey.
myos corp (MYOS) Top Compensated Officers
myos corp (MYOS) Key Developments
MYOS Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported revenue of $277,374 against $24,541 a year ago. Loss from operations was $1,092,059 against $423,024 a year ago. Net loss was $1,090,194 against $498,851 a year ago. Basic and diluted net loss per share attributable to common stockholders was $0.01 against $0.01 a year ago.
On April 25, 2013, Glen R. Fleischer resigned from his position as Chief Executive Officer of MYOS Corporation and as a member of its board of directors. On April 21, 2013, Peter Levy, the company’s existing Chief Operating Officer, was appointed to the additional position of President of the company. In this capacity, Mr. Levy will serve as the company’s principal executive officer.
MYOS Corp. reported consolidated earnings results for the fourth quarter and year ended December 31, 2012. For the quarter, the company reported revenue of $177,364 against $43,634 a year ago. Loss from operations was $1,021,884 against $896,503 a year ago. Net loss was $1,018,174 against $1,807,227 a year ago. For the year, the company reported revenue of $911,727 against $99,475 a year ago. Loss from operations was $3,035,493 against $4,596,220 a year ago. Net loss was $3,914,460 against $5,597,300 a year ago.
| Recently Viewed | |||
| MYOS:US | $0.12 USD | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for MYOS. | |||
| View Industry Companies | |||
Industry Analysis
MYOS
Industry Average
| Valuation | MYOS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 11.8x |
|
| Price/Book | 2.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 8.8x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Northglenn, CO | Office DepotPosted: Mar 01
Sponsored Financial Commentaries
Sponsored Links
To contact MYOS CORP, please visit www.myoscorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








